Reports
Sale
Global Neoantigen Cancer Vaccine Market Size, Share, Report: By Product Type: Personalized Neoantigen Vaccine, Off-the Shelf Neoantigen Vaccine; By Neoantigen Type; By Route of Administration; By Cell; By Technology; By Delivery Mechanism; By Applications; Regional Analysis; Market Dynamics; Supplier Landscape; 2024-2032
Global Neoantigen Cancer Vaccine Market Outlook
The global neoantigen cancer vaccine market size was valued at USD 116.74 million in 2023, driven by the rising investments in the research and development of the immunotherapy and rapid technological advancements in the healthcare sector. The market size is anticipated to grow at a CAGR of 69.43% during the forecast period of 2024-2032 to achieve a value of USD 13,431.43 million by 2032.
Neoantigen Cancer Vaccine: Introduction
Neoantigens are tumour-specific antigens produced in cancer cells that signify the changes which happen throughout the transformative process. These substances are truly unique to cancer tissue and have the potential to be identified by the immune system, resulting in the host's distinct anti-tumour activity. Neoantigens are peptides that are abnormally expressed as a result of genome alterations and are translated to form live peptides. They function as mechanisms for the immune system to distinguish between own and tumour tissue and have been identified as a novel target for cancer immunotherapies.
Global Neoantigen Cancer Vaccine Market Analysis
There are several key trends propelling the growth of the market size. The introduction of immunotherapy has emerged as a groundbreaking approach in cancer treatment and neoantigen cancer vaccines as a form of immunotherapy that specifically target neoantigens, which are tumour-specific antigens derived from genetic mutations has proven to be transformative in the approach to treat cancer. The increasing understanding of the immune system and its role in fighting cancer has fuelled the neoantigen cancer vaccines market demand further. The interest in neoantigen cancer vaccines has also spurred a significant increase in research and clinical trials which further has caused global neoantigen cancer vaccine market to witness dynamic growth.
Global Neoantigen Cancer Vaccine Market Segmentations
Based on segments, the market is divided into product type, neoantigen type, route of administration, cell, technology, delivery mechanism, applications, and region.
Market Breakup by Product Type
- Personalized Neoantigen Vaccine
- Off-the Shelf Neoantigen Vaccine
Market Breakup by Neoantigen Type
- Synthetic Long Peptide (SLP)
- Dendritic Cell
- Nucleic Acid
- Tumour Cell
Market Breakup by Route of Administration
- Intravenous
- Intramuscular
- Transdermal
- Others
Market Breakup by Cell
- Autologous
- Allogenic
Market Breakup by Technology
- RNA Sequencing
- Whole Genome Sequencing
- HLA Typing
- Others
Market Breakup by Delivery Mechanism
- Liposomes
- Virosomes
- Electroporation
- Gene Gun
- Others
Market Breakup by Applications
- Lung, Melanoma
- Gastrointestinal
- Brain Cancer
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Neoantigen Cancer Vaccine Market Scenario
The market has a lot of room to expand since immunotherapeutic treatment research and development is still ongoing, both in terms of understanding their mechanism of action, clinical relevance, and usability. The research and clinical trials in the field of immunotherapy is receiving enormous amounts of financial support from pharmaceutical corporations, biotech businesses, and academic institutions which has led to further growth capabilities for global neoantigen cancer vaccine market.
Global Neoantigen Cancer Vaccine Market: Competitor Landscape
The comprehensive EMR report provides an in-depth assessment of the market based on Porter's five forces model, along with giving a SWOT analysis. The report gives a detailed analysis of the following neoantigen cancer vaccine companies, covering their competitive landscape and the latest developments like mergers, acquisitions, investments, and expansion plans.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- OSE Immunotherapeutics SA
- Gritstone bio, Inc.
- BioNTech SE
- F. Hoffmann-La Roche Ltd.
- Pfizer Inc.
- Merck & Co. Inc.
- Moderna Inc.
- Avidea Technologies, Inc.
- Eli Lilly and Company
- Vaccibody AS
- Agenus Inc.
- Novogene Co., Ltd.
- ZIOPHARM Oncology Inc.
- ISA Pharmaceuticals B.V.
- BrightPath Biotherapeutics Co., Ltd.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product Type |
|
| Breakup by Neoantigen Type |
|
| Breakup by Route of Administration |
|
| Breakup by Cell |
|
| Breakup by Technology |
|
| Breakup by Delivery Mechanism |
|
| Breakup by Applications |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Neoantigen Cancer Vaccine Market Overview
3.1 Global Neoantigen Cancer Vaccine Market Historical Value (2017-2023)
3.2 Global Neoantigen Cancer Vaccine Market Forecast Value (2024-2032)
4 Global Neoantigen Cancer Vaccine Market Landscape
4.1 Global Neoantigen Cancer Vaccine Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Neoantigen Cancer Vaccine Product Landscape
4.2.1 Analysis by Product Type
4.2.2 Analysis by Technology
4.2.3 Analysis by Route of Administration
4.2.4 Analysis by Applications
5 Global Neoantigen Cancer Vaccine Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Neoantigen Cancer Vaccine Market Segmentation
6.1 Global Neoantigen Cancer Vaccine Market by Product Type
6.1.1 Market Overview
6.1.2 Personalized Neoantigen Vaccine
6.1.3 Off-the Shelf Neoantigen Vaccine
6.2 Global Neoantigen Cancer Vaccine Market by Neoantigen Type
6.2.1 Market Overview
6.2.2 Synthetic Long Peptide (SLP)
6.2.3 Dendritic Cell
6.2.4 Nucleic Acid
6.2.5 Tumour Cell
6.3 Global Neoantigen Cancer Vaccine Market by Route of Administration
6.3.1 Market Overview
6.3.2 Intravenous
6.3.3 Intramuscular
6.3.4 Transdermal
6.3.5 Others
6.4 Global Neoantigen Cancer Vaccine Market by Cell
6.4.1 Market Overview
6.4.2 Autologous
6.4.3 Allogenic
6.5 Global Neoantigen Cancer Vaccine Market by Technology
6.5.1 Market Overview
6.5.2 RNA Sequencing
6.5.3 Whole Genome Sequencing
6.5.4 HLA Typing
6.5.5 Others
6.6 Global Neoantigen Cancer Vaccine Market by Delivery Mechanism
6.6.1 Market Overview
6.6.2 Liposomes
6.6.3 Virosomes
6.6.4 Electroporation
6.6.5 Gene Gun
6.6.6 Others
6.7 Global Neoantigen Cancer Vaccine Market by Applications
6.7.1 Market Overview
6.7.2 Lung, Melanoma
6.7.3 Gastrointestinal
6.7.4 Brain Cancer
6.7.5 Others
6.8 Global Neoantigen Cancer Vaccine Market by Region
6.8.1 Market Overview
6.8.2 North America
6.8.3 Europe
6.8.4 Asia Pacific
6.8.5 Latin America
6.8.6 Middle East and Africa
7 North America Neoantigen Cancer Vaccine Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Neoantigen Cancer Vaccine Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Neoantigen Cancer Vaccine Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Neoantigen Cancer Vaccine Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Neoantigen Cancer Vaccine Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 OSE Immunotherapeutics SA
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisition
17.1.5 Certifications
17.2 Gritstone bio, Inc.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisition
17.2.5 Certifications
17.3 BioNTech SE
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisition
17.3.5 Certifications
17.4 F. Hoffmann-La Roche Ltd.
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisition
17.4.5 Certifications
17.5 Pfizer Inc.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisition
17.5.5 Certifications
17.6 Merck & Co. Inc.
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisition
17.6.5 Certifications
17.7 Moderna Inc.
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisition
17.7.5 Certifications
17.8 Avidea Technologies, Inc.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisition
17.8.5 Certifications
17.9 Eli Lilly and Company
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisition
17.9.5 Certifications
17.10 Vaccibody AS
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisition
17.10.5 Certifications
17.11 Agenus Inc.
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisition
17.11.5 Certifications
17.12 Novogene Co., Ltd.
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisition
17.12.5 Certifications
17.13 ZIOPHARM Oncology Inc.
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisition
17.13.5 Certifications
17.14 ISA Pharmaceuticals B.V.
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisition
17.14.5 Certifications
17.15 BrightPath Biotherapeutics Co., Ltd.
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisition
17.15.5 Certifications
18 Global Neoantigen Cancer Vaccine Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of USD 116.74 million in 2023.
The market size is anticipated to grow at a CAGR of 69.43% during the forecast period of 2024-2032 to attain a value of around USD 13,431.43 million in 2032.
The growth of the market is driven by factors like rising investments in the research and development of the immunotherapy and rapid technological advancements in the healthcare sector.
The introduction of immunotherapy has emerged as a groundbreaking approach in cancer treatment and neoantigen cancer vaccines as a form of immunotherapy that specifically target neoantigens, which are tumour-specific antigens derived from genetic mutations has proven to be transformative in the approach to treat cancer.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
The different types of products in the market are personalized neoantigen vaccine and off-the shelf neoantigen vaccine.
The neoantigen types include synthetic long peptide (SLP), dendritic cell, nucleic acid, and tumour cell.
The route of administration can be categorised into intravenous, intramuscular, and transdermal, among others.
The cell types can be categorised into autologous and allogenic.
The different delivery mechanism in the market includes liposomes, virosomes, electroporation, and gene gun, among others.
The different technologies used in the market are RNA sequencing, whole genome sequencing, and HLA typing. among other.
The vaccine finds wide applications in the treatment of lung, melanoma, gastrointestinal, and brain cancer, among others.
Key players involved in the market includes OSE Immunotherapeutics SA, Gritstone bio, Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., Merck & Co. Inc., Moderna Inc., Avidea Technologies, Inc., Eli Lilly and Company, Vaccibody AS, Agenus Inc., Novogene Co., Ltd., ZIOPHARM Oncology Inc., ISA Pharmaceuticals B.V., BrightPath Biotherapeutics Co., Ltd., and BioNTech SE.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER